Monday, December 23, 2024
HomeTagsIndependent review committee

independent review committee

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

BeiGene, Ltd, a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BRUKINSA® (zanubrutinib) for the...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics